


ANNEXURE IX TO CLAUSE 41

Standalone Statement of Assets and Liabilities		(Rs. In Lacs)	
		As at Year ended 31st Mar 2016 (Audited)	As at Year ended 31st Mar 2015 (Audited)
A EQUITY AND LIABILITIES			
1	Share Holders Fund		
	(a) Share Capital	7,577.00	7,577.00
	(b) Reserves and Surplus	8,139.53	10,237.86
	(c) Money Received against Share Warrants	-	-
	Sub Total - Share Holders' Fund	15,716.53	17,814.86
2	Share Application Money pending allotment	-	-
3	Minority Interest	-	-
4	Non-Current Liabilities		
	(a) Long Term Borrowings	626.69	626.69
	(b) Deferred Tax Liabilities (Net)	-	-
	(c) Other Long-Term Liabilities	-	-
	(d) Long-term Provisions	12,087.86	12,087.86
	Sub-Total- Non Current Liabilities	12,714.55	12,714.55
5	Current Liabilities		
	(a) Short Term Borrowings	907.89	807.20
	(b) Trade Payables	77.28	1,560.47
	(c) Other Current Liabilities	144.61	135.55
	(d) Short-term Provisions	-	-
	Sub-Total- Current Liabilities	1,129.78	2,503.22
	TOTAL EQUITY AND LIABILITIES	29,560.86	33,032.64
B ASSETS			
1	Non-Current Assets		
	(a) Fixed Assets	14,377.45	16,369.32
	(b) Goodwill on Consolidation	-	-
	(c) Non- Current Investments	9,220.10	9,220.10
	(d) Deferred Tax Assets (Net)	-	-
	(e) Long-term Loans and Advances	2,420.85	2,419.07
	(f) Other Non Current Assets	3,198.85	3,198.85
	Sub - total -Non Current Assets	29,217.25	31,207.34
2	Current Assets		
	(a) Current Investments	-	-
	(b) Inventories	6.62	6.62
	(c) Trade Receivables	162.64	1,638.91
	(d) Cash and Cash Equivalent	1.05	3.01
	(e) Short-term Loans and Advances	173.30	176.76
	(f) Other Current Assets	-	-
	Sub-total- Current Assets	343.61	1,825.30
	TOTAL ASSETS	29,560.86	33,032.64

Place: Hyderabad
Date: 30/05/2016



For and on behalf of the Board of Directors

 Dr K Koteswara Rao
 Chairman & Managing Director

Annexure IV to Clause 41
Reporting of Segment wise Revenue, Results and Capital Employed along with the quarterly results

S.No	PARTICULARS	(Rs. In Lakhs)			
		Quarter Ended 31.03.2016 (Audited)	Quarter Ended 31.12.2015 (Unaudited)	Quarter Ended 31.03.2015 (Audited)	Year Ended 31.03.2016 (Audited)
1	SEGMENT REVENUE				
	a) Segment -A Diagnostic Services	2.78	4.87	4.56	17.85
	b) Segment -B Agri Division	-	-	-	-
	c) Segment -C Bulk Drugs Trading	-	-	-	-
	d) Segment -D CRO Services	-	-	-	-
	e) Segment -E API-DHA	-	-	-	-
	f) Segment -F Others	5.85	6.96	1.35	16.91
	Total:	8.62	11.83	5.91	34.75
	Less: Inter Segment Revenue	-	-	-	-
	Net Sales/Income From Operation	8.62	11.83	5.91	34.75
2	SEGMENT RESULTS				
	(Profit /Loss Before Tax & Interest from each Segment)				
	a) Segment -A Diagnostic services	1.14	0.05	-3.31	1.75
	b) Segment -B Agri Division	-	-	-	-
	c) Segment -C Bulk Drugs Trading	-	-	-	-
	d) Segment -D CRO Services	-	-	-	-
	e) Segment -E API-DHA	-	-	-	-
	f) Segment -F Other Unallocated	-268.74	-713.95	-455.30	-1,897.62
	g) R & D Expenses	-0.01	-0.02	-1.47	-0.18
	Total Segmental Result	-267.62	-713.92	-460.09	-1,896.05
	Other Income	-	-	-	-
	Total	-267.62	-713.92	-460.09	-1,896.05
	Less: Interest & Finance Charges	0.01	0.02	0.30	0.16
	Less: Unallocable expenses	-	-	-	-
	Exceptional items-forex fluctuation/(gain)/Loss	-	-	-	-
	Total Profit/Loss Before Tax	-267.63	-713.94	-460.39	-1,896.21
3	CAPITAL EMPLOYED				
	a) Segment - A Diagnostic services	324.83	324.83	324.83	324.83
	b) Segment - B Agri Division	-	-	-	-
	c) Segment -C Bulk Drugs	24,090.93	24,090.93	24,090.93	24,090.93
	Total	24,415.76	24,415.76	24,415.76	24,415.76



For TRANSGENE BIOTEK LTD.

[Signature]

MANAGING DIRECTOR

Place: Hyderabad
Date: 30/05/2016

TRANSGENE BIOTEK LIMITED
68,69,&70, ANRICH INDUSTRIAL AREA
BOLLARAM, MEDAK DISTRICT

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31.03.2016

(Rs. In Lakhs)

Particulars	Quarter ended 31.03.2016	Quarter ended 31.12.2015	Quarter ended 31.03.2015	For year ended 31.03.2016	For Previous year ended 31.03.2015
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1 (a) Net Sales/Income from Operations	8.62	11.83	5.91	34.73	33.28
(b) Other Operating Income	-	-	-	-	-
2. Expenditure					
a. Increase/decrease in stock in trade and work in progress	-	-	-	-	0.19
b. Consumption of raw materials	-	-	0.10	-	1.23
2 c. Purchase of traded goods	-	-	-	-	-
d. Employees cost	14.88	18.01	23.56	68.15	119.21
e. Depreciation	245.76	687.68	423.62	1,796.73	1,718.05
f. Other expenditure	15.61	20.06	18.70	65.91	82.48
Total	276.24	725.75	465.99	1,930.80	1,921.17
3 Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	-267.62	-713.92	-460.09	-1,896.05	-1,887.90
4 Other Income	-	-	-	-	-
5 Profit / (loss) from Ordinary activities before finance cost and exceptional items(3+4)	-267.62	-713.92	-460.09	-1,896.05	-1,887.90
6 Finance Cost	0.01	0.02	0.30	0.16	32.40
7 Profit / (loss) from ordinary activities after finance cost but before Exceptional Items (5-6)	-267.63	-713.94	-460.39	-1,896.21	-1,920.30
8 Prior Period Expenses/ (income)	-	-	-	-	0.60
9 Profit (+)/ Loss (-) from Ordinary Activities before tax (7+8)	-267.63	-713.94	-460.39	-1,896.21	-1,920.90
10 Tax expense	-	-	-	-	-
11 Net Profit (+)/ Loss (-) from Ordinary Activities after tax (9-10)	-267.63	-713.94	-460.39	-1,896.21	-1,920.90
12 Extraordinary Item (net of tax expense if any)	-	-	-	-	-
13 Net Profit(+)/ Loss(-) for the period (11-12)	-267.63	-713.94	-460.39	-1,896.21	-1,920.90
14 Share of profit/(loss) of associates	-	-	-	-	-
15 Minority Interest	-	-	-	-	-
16 Net Profit(+)/ Loss(-) after taxes, Minority interest and share of profit/(Loss) of associates (13-14-15))	-267.63	-713.94	-460.39	-1,896.21	-1,920.90
17 Paid-up equity share capital (Face value of share of Rs 10/- each)	7,577.00	7,577.00	7,577.00	7,577.00	7,577.00
No of Shares	75,770,000	75,770,000	75,770,000	75,770,000	75,770,000
18 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	8,139.53	8,403.23	12,141.45	8,139.53	12,141.45
Earnings Per Share (EPS)					
a) Basic EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	-0.35	-0.94	-0.61	-2.50	-2.54
b) Diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	-0.35	-0.94	-0.61	-2.50	-2.54
c) Basic EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	-0.35	-0.94	-0.61	-2.50	-2.54
d) Diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	-0.35	-0.94	-0.61	-2.50	-2.54
Public Shareholding					
20 No. of shares	59,342,098	59,342,098	59,342,098	59,342,098	59,342,098
Percentage of shareholding	78.32	78.32	78.32	78.32	78.32
Promoters and promoter group Shareholding **	16,427,902	16,427,902	16,427,902	16,427,902	16,427,902
a) Pledged/Encumbered	-	-	-	-	-
Number of shares	-	-	-	-	-
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
21 Percentage of shares (as a% of the total share capital of the company)	-	-	-	-	-
b) Non-encumbered	-	-	-	-	-
Number of Shares	16,427,902	16,427,902	16,427,902	16,427,902	16,427,902
Percentage of shares (as a% of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
Percentage of shares (as a % of the total share capital of the company)	21.68	21.68	21.68	21.68	21.68

Notes to the Results

1) Due to stiff competition from the Chinese companies, DHA sales have been adversely impacted. However, the commercial sales of this product have started to operate from the beginning of 2016-17 onwards.

2) The discussions with multinational companies on Oral Insulin/oral delivery of peptides are reaching the next important milestone.

3) With performance of one of the Medical Centers continuing to decline, the management has decided to close this operation at this center with the approval of the board.

4) No. of Investor complaints pending at the beginning of the quarter - Nil; received during the quarter - Nil; resolved during the quarter - Nil; pending unresolved at the end of the quarter - Nil.

5) The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 30th May 2016.

Place: Hyderabad
Date: 30/05/2016



For TRANSGENE BIOTEK LTD.

[Signature]

MANAGING DIRECTOR

Auditor's Report on Quarterly Financial Results & Year to Date Financial Results of **TRANSGENE BIOTEK LIMITED** Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

To
Board of Directors
TRANSGENE BIOTEK LIMITED.
Hyderabad

We have audited the quarterly financial results of **TRANSGENE BIOTEK LIMITED** ("Company") for the quarter ended 31st March, 2016 and the year to date financial results for the period from 1st April, 2015 to 31st March, 2016 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) for interim financial Reporting (AS-25), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.


We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanation given to us these quarterly financial results as well as the year to date financial results:

- i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 in this regard; and
- ii) give a true and fair view of the net profit and other financial information for the quarter ended 31st March, 2016 as well as the year to date financial results for the period from 1st April, 2015 to 31st March, 2016.

Place : Hyderabad
Date : 30.05.2016

For **GOPAL & RAJAN**
Chartered Accountants



K. GOUTHAM SUBBIAH
Partner

M.No.203237

FRN.0009535